ReviewCleveland Clinic journal of medicine2011
Immune thrombocytopenia: no longer 'idiopathic'.
Review in Cleveland Clinic journal of medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 94 citations in OpenAlex.
- A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.Journal of hematology & oncology · 2021Trial
- Patient and Physician Experiences in Immune Thrombocytopenia.Advances in therapy · 2026Article
- Article
- Evaluation and validation of the prognostic value of platelet indices in patients with leukemia.Clinical and experimental medicine · 2023Review
- Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP.Blood advances · 2023Review
- Overuse of corticosteroids in patients with immune thrombocytopenia (ITP) between 2011 and 2017 in the United States.EJHaem · 2023Article
- Oral Manifestations in Children Diagnosed with COVID-19: A Narrative Review.Healthcare (Basel, Switzerland) · 2023Review
- Immune Thrombocytopenia Relapse in Patients Who Received mRNA COVID-19 Vaccines.Journal of blood medicine · 2023Article
- Significance of TLR2 signaling during megakaryocyte development: regulatory cross-talk of miR-125b, cytokine induction, and MAPK pathway during dengue infection.American journal of translational research · 2023Article
- Successful Eltrombopag Therapy in a Child with MYH9-Related Inherited Thrombocytopenia.Children (Basel, Switzerland) · 2022Article
- Quick drop of platelet counts in children with chronic immune thrombocytopenia after COVID-19 mRNA vaccination: case reports.Clinical and experimental vaccine research · 2022Article
- Investigation of the correlation between immune thrombocytopenia and T cell activity-regulated gene polymorphism using functional study.Scientific reports · 2022Article
- Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease.Expert review of respiratory medicine · 2022Review
- Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia.Journal of blood medicine · 2022Article
- Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of a Romiplostim Biosimilar in Chronic Refractory Immune Thrombocytopenic Purpura (ITP) Patients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022Article
- Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives.Open access emergency medicine : OAEM · 2022Review
- Severe Thrombocytopenic Purpura Associated with COVID-19 in a Pediatric Patient.Infection and drug resistance · 2022Article
- Splenectomy in patients with immune (idiopathic) thrombocytopenic purpura (ITP) appears to be protective against developing aortic valve disease.American journal of blood research · 2022Article
- Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids.International journal of hematology · 2021Article
- Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern.Research and practice in thrombosis and haemostasis · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis involves both accelerated platelet destruction and impaired platelet production. First-line agents are usually effective initially but do not provide long-term responses. Splenectomy remains an effective long-term therapy, as does rituximab (Rituxan) in a subset of patients. Thrombopoietic agents offer a new alternative, although their place in the overall management of ITP remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.